Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Size & Outlook
The anti-vascular endothelial growth factor therapeutics market in Asia Pacific is expected to reach a projected revenue of US$ 402.5 million by 2030. A compound annual growth rate of -7.9% is expected of Asia Pacific anti-vascular endothelial growth factor therapeutics market from 2025 to 2030.
Pharmaceuticals
Ophthalmology Drugs
Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
Asia Pacific anti-vascular endothelial growth factor therapeutics market highlights
The Asia Pacific anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 637.5 million in 2024.
The market is expected to grow at a CAGR of -7.9% from 2025 to 2030.
In terms of segment, eylea was the largest revenue generating product in 2024.
Vabysmo is the most lucrative product segment registering the fastest growth during the forecast period.
Country-wise, China is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
Market revenue in 2024
USD 637.5 million
Market revenue in 2030
USD 402.5 million
Growth rate
-7.9% (CAGR from 2025 to 2030)
Largest segment
Eylea
Fastest growing segment
Vabysmo
Historical data covered
2018 - 2023
Base year for estimation
2024
Forecast period covered
2025 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Eylea, Lucentis, Beovu, Vabysmo
Key market players worldwide
Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc
Other key industry trends
In terms of revenue, Asia Pacific region accounted for 4.4% of the global anti-vascular endothelial growth factor therapeutics market in 2024.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
North America is the fastest growing regional market and is projected to reach USD 9,124.8 million by 2030.
Asia Pacific is expected to exhibit a significant CAGR over the forecast period due to increasing market opportunities and growing healthcare expenditure. Licensing agreements between companies and increasing demand for anti-VEGF products can support market growth over the coming years.
Furthermore, increase in initiatives undertaken by governments for improving health of population is expected to drive market growth during the forecast period. Improving access to anti-VEGF drugs through favorable reimbursement policies in high-income countries of Asia Pacific can fuel the market by boosting adoption.
In Australia, the inclusion of anti-VEGF products in the PBS can support market growth. However, the presence of generic players in the market can limit market growth.
Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 52.91% in 2024.
Horizon Databook has segmented the Asia Pacific anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to exhibit a significant CAGR over the forecast period due to increasing market opportunities and growing healthcare expenditure. Licensing agreements between companies and increasing demand for anti-VEGF products can support market growth over the coming years.
Furthermore, increase in initiatives undertaken by governments for improving health of population is expected to drive market growth during the forecast period. Improving access to anti-VEGF drugs through favorable reimbursement policies in high-income countries of Asia Pacific can fuel the market by boosting adoption.
In Australia, the inclusion of anti-VEGF products in the PBS can support market growth. However, the presence of generic players in the market can limit market growth.
Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Product Outlook (Revenue, USD Million , 2018-2030)
Eylea
Lucentis
Beovu
Vabysmo
Others
Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Disease Outlook (Revenue, USD Million , 2018-2030)
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
Myopic Choroidal Neovascularization
Reasons to subscribe to Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook databook
Our clientele includes a mix of Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, 2018-2030 (US$M)